A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

NCT06997627 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus-diphtheria-acellular Pertussis (Tdap)

Interventions

BIOLOGICAL: GC3111B
BIOLOGICAL: Boostrix®

Sponsor

GC Biopharma Corp